KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Asset Writedowns and Impairment (2020 - 2024)

Vir Biotechnology's Asset Writedowns and Impairment history spans 3 years, with the latest figure at $11.0 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment rose 300.07% year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, down 20.0%, while the annual FY2024 figure was $14.6 million, 50.65% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was $11.0 million at Vir Biotechnology, up from $2.8 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $11.0 million in Q4 2024 and bottomed at $800000.0 in Q3 2020.
  • The 3-year median for Asset Writedowns and Impairment is $2.8 million (2023), against an average of $4.9 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 300.07% in 2024 against a maximum downside of 300.07% in 2024.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $800000.0 in 2020, then surged by 244.88% to $2.8 million in 2023, then soared by 300.07% to $11.0 million in 2024.
  • Per Business Quant, the three most recent readings for VIR's Asset Writedowns and Impairment are $11.0 million (Q4 2024), $2.8 million (Q4 2023), and $800000.0 (Q3 2020).